Reset filter
Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

702 Search results.

Relevance Rating New first Old first

Screening - GSK Milveterol COPD 100527

- 9/20/21 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria,Demography,Duration of Asthma,Vital Signs,12-Lead Electrocardiogram,Pulmonary function,Hematology,Clinical Chemistry,Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Pleural Mesothelioma Malignant Advanced NCT02029690

- 9/27/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin; ODM derived from: https://clinicaltrials.gov/show/NCT02029690

GAP index and staging system

- 9/27/21 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: GAP index and staging system
The GAP index and staging system is a multidimensional prognostic staging system using commonly measured clinical and physiologic variables to predict mortality in patients with idiopathic pulmonary fibrosis (IPF). Reference: Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., ... & King, T. E. (2012). A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of internal medicine, 156(10), 684-691.

Eligibility Pulmonary Arterial Hypertension NCT00709956

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Iloprost Power 15 in Pulmonary Arterial Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00709956

Eligibility Pulmonary Arterial Hypertension NCT00617305

- 9/27/21 - 1 form, 1 itemgroup, 17 items, 1 language
Itemgroup: Criteria
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1); ODM derived from: https://clinicaltrials.gov/show/NCT00617305

Eligibility Lung Cancer NCT00955942

- 9/27/21 - 1 form, 1 itemgroup, 17 items, 1 language
Itemgroup: Criteria
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00955942

Eligibility Obstructive Sleep Apnea and Diabetes Mellitus NCT01136785

- 9/27/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Effects of Continuous Positive Airway Pressure (CPAP)Treatment on Glucose Control; ODM derived from: https://clinicaltrials.gov/show/NCT01136785

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02409342

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]; ODM derived from: https://clinicaltrials.gov/show/NCT02409342

Eligibility Non-Small Cell Lung Cancer NCT02515435

- 9/27/21 - 1 form, 2 itemgroups, 22 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02515435

clinic internal medicine B SHIP-Trend-0 BPG: spirometry

- 9/20/21 - 1 form, 1 itemgroup, 8 items, 2 languages
Itemgroup: BPG: spirometry
BPG: spirometry form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.IMB.BPG.SPIROMET. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Eligibility Bronchial Asthma NCT01414868

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA); ODM derived from: https://clinicaltrials.gov/show/NCT01414868

Eligibility Non-Small-Cell Lung Cancer NCT00705549

- 9/20/21 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00705549

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial